A senior Biogen commercial exec exits Alzheimer's unit amid exodus as Aduhelm woes mount

One of Biogen’s senior commercial execs on the Alzheimer’s side of the business is exiting the troubled company after a series of setbacks suffered during a failed attempt to launch their controversial drug Aduhelm.

Johanna Rossell, a Novartis commercial vet who had been Biogen’s global commercial lead for the Alzheimer’s business unit, completed her last day of work at Biogen yesterday, according to a company spokesperson. Enzyvant — a Roivant startup acquired by Sumitomo Dainippon — announced that she had joined them as their new commercial chief earlier today. She’s one of 3 Novartis vets that just landed new roles running commercial ops in biotech.